Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer or HER+ Breast cancer that has spread to the brain (brain metastasis). Dendritic cell vaccines work by boosting the immune system (a system in the body that protect against infection) to recognize and destroy the cancer cells. . Pembrolizumab is an "immune checkpoint inhibitor" which is designed to either "unleash" or "enhance" the cancer immune responses that already exist by either blocking inhibitory molecules" or by activating stimulatory molecules. Giving dendritic cell vaccines and pembrolizumab may shrink the cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta, która nie jest w ciąży i nie karmi piersią
- •Kobieta w wieku rozrodczym, która zobowiązuje się do stosowania antykoncepcji przez cały czas badania i co najmniej 2 lata po ostatnim leczeniu
- •Negatywny test na ciążę (test krwi i moczu) wykonany przed włączeniem do badania
- •Potwierdzony rozpoznanie raka piersi typu triple negative (TNBC) - brak receptorów estrogenowych, progesteronowych i HER2
- •Lub potwierdzony rozpoznanie raka piersi dodatniego na hormony (HR+)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (3)
Moffitt Cancer Center
Tampa, United States
Roswell Park Cancer Institute
Buffalo, United States
University of Virginia Comprehensive Cancer Center
Charlottesville, United States
Trial contact
Sheheryar Kabraji, BMBCh
Sheheryar Kabraji
PRINCIPAL_INVESTIGATOR
Patrick Dillon, MD
Patrick Dillon, MD
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.